Investigational drug for advanced Non-Small Cell Lung Cancer
Michael P. Kosty, M.D.
This study will compare the safety and effectiveness of an investigational drug called nivolumab, in combination with other drugs already used to treat advanced non-small cell lung cancer (NSCLC). Nivolumab is an antibody (a type of human protein) that might allow the body’s immune system to work against tumor cells.
Be 18 years of age or older
Have recurrence of locally advanced or Stage 4 NSCLC
Have tumor with positive EGFR mutation and negative ALK translocation mutation
Have received treatment for local NSCLC less than 6 months prior to disease recurrence
Have received treatment for recurrence of locally advanced or Stage 4 NSCLC
Be pregnant, planning to become pregnant, or breastfeeding
Have a positive test for hepatitis B virus, hepatitis C virus, or a history of HIV virus infection
Patients in this study will be assigned by chance to receive either nivolumab with erlotinib OR erlotinib alone.